Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN

Wells Fargo & Company MN raised its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 23.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,653 shares of the company’s stock after acquiring an additional 13,196 shares during the period. Wells Fargo & Company MN’s holdings in Neumora Therapeutics were worth $749,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Swiss National Bank acquired a new stake in shares of Neumora Therapeutics in the 4th quarter worth approximately $1,168,000. Barclays PLC lifted its position in Neumora Therapeutics by 352.9% in the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after purchasing an additional 100,678 shares during the period. KLP Kapitalforvaltning AS bought a new position in Neumora Therapeutics during the 4th quarter valued at $143,000. Vanguard Group Inc. boosted its stake in Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock valued at $48,466,000 after purchasing an additional 195,142 shares in the last quarter. Finally, Arizona State Retirement System acquired a new position in shares of Neumora Therapeutics during the 4th quarter valued at $172,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright decreased their target price on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, April 10th. Stifel Nicolaus downgraded shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $6.00 to $2.00 in a report on Friday, March 7th. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.29.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA opened at $0.77 on Friday. The firm has a 50 day simple moving average of $1.03 and a 200 day simple moving average of $5.38. Neumora Therapeutics, Inc. has a 52 week low of $0.62 and a 52 week high of $17.19. The company has a market cap of $124.77 million, a PE ratio of -0.41 and a beta of 2.89.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, equities analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.